The European Commission (EC) has approved Pfizer’s drug Vizimpro (dacomitinib) as a monotherapy to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC).

The approval allows use of the drug as a first-line therapy in patients with epidermal growth factor receptor (EGFR)-activating mutations.

Vizimpro is an oral, irreversible pan-human EGFR kinase inhibitor.

The drug’s regulatory approval is based on results from the Phase III ARCHER 1050 clinical trial performed in a total of 452 unresectable, metastatic or recurrent NSCLC patients with EGFR exon 19 deletion or exon 21 L858R substitution mutations.

During the trial, 45mg Vizimpro was compared to 250mg gefitinib.

Primary endpoint of the randomised, multi-centre, multi-national, open-label study was progression-free survival (PFS). It also assessed secondary endpoints, including objective response rate (ORR), duration of response (DoR) and overall survival (OS).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Vizimpro has shown a more than five-month improvement in progression-free survival over an existing therapy in a Phase III clinical trial.”

The trial met its primary endpoint with statistically significant improvement in PFS when treated with Vizimpro, compared to gefitinib.

Final analysis demonstrated an increase of 7.3 months in median OS in the Vizimpro arm.

Among 227 patients treated with Pfizer’s drug, 6.2% experienced serious adverse reactions. The most common serious adverse reactions were diarrhoea and interstitial lung disease.

Pfizer partnered with SFJ Pharmaceuticals in 2012 to conduct the trial at multiple clinical sites.

Pfizer Oncology International Developed Markets regional president Andreas Penk said: “The marketing authorization of Vizimpro, which has shown a more than five-month improvement in progression-free survival over an existing therapy in a Phase III clinical trial, provides a new option for patients with EGFR-mutated non-small cell lung cancer and reinforces Pfizer’s ongoing commitment to addressing the remaining needs of the thousands of EU patients with this disease.”

The drug also holds the US regulatory approval as first-line treatment for metastatic NSCLC patients with EGFR exon 19 deletion or exon 21 L858R substitution mutations.

It also has Japanese and Canadian approvals for treating specific NSCLC patients.